24% is better than nothing, but now they're going to have to do another trial "enrolling 140 critically ill COVID-19 patients with the primary endpoint defined as length of hospital stay." They're changing the primary endpoint.
So, probably no EUA in the near future. The new trial will likely take 3-5 months. Meanwhile, they'll try to sell leronlimab in some other country. Basically, the trial failed to meet its primary endpoint, they're going after only critically ill patients now, not including severe, I don't see any immediate catalyst for the stock.
The share price usually bombs after conference calls. They're holding one today at 4:00 eastern. Looks like a rough week.
